Role of highly avid antitoxic antibodies in the estimation of insusceptibility to diphtheria infection



如何引用文章

全文:

详细

A procedure was developed to determine the avidity of antitoxic antidiphtheria antibodies, by using the enzyme immunoassay. It was shown that both total antibodies and their avidity might be estimated in one test. A study of sera from healthy vaccinees could define differences in the time course of changes in the accumulation and loss of both total and highly avid antitoxic antidiphtheria antibodies. Maturation of highly avid antibodies took place more slowly than the total number of antibodies increased whereas loss of highly avid antibodies occurred much more quickly than the total count of antibodies decreased. Five years following regular revaccination, the antibody avidity index achieved its minimal (critical) level while the content of antitoxic antibodies was reduced to critical values (0.01 IU/ml) at 7-8 years after revaccination. Risk groups were identified among the examinees. These included subjects aged over 50 years, medical workers, industrial workers, particularly those engaged in hazardous occupations, subjects with chronic somatic and infectious diseases, and those vaccinated against diphtheria more than 5 years ago.

作者简介

Lyudmila Kraeva

Email: lykraeva@eandex.ru

Galina Tseneva

Alla Nikolaeva

Email: nikolaeva.alla@gmail.com; a.m.nikolaeva@ mail.ru

Elena Alekseeva

Email: elenaalekseeva182@rambler.ru

L Krayeva

Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare

Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare

G Tseneva

Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare

Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare

A Nikolayeva

Biomed Research-and-Production Association

Biomed Research-and-Production Association

E Alekseyeva

Center for Hygiene and Epidemiology in the Vologda Region

Center for Hygiene and Epidemiology in the Vologda Region

参考

  1. Васильев К. Г., Савчук А. И. Клинико-эпидемиологические аспекты вакцинации против дифтерии // Первый Конгресс педиатров-инфекционистов России. - М., 2002. - С. 26.
  2. Галазка А. Иммунологические основы иммунизации. Вып. 1: Общая иммунология. - Женева, 1993.
  3. Краева Л. А., Носков Ф. С., Ценева Г. Я Качественные показатели антитоксических антител в оценке противодифтерийного иммунитета // Мед. иммунол. - 2005. - Т. 7, № 2-3. - С. 274.
  4. Кэтти Д. Антитела. Методы: Пер. с англ. - М., 1991. - Кн. 1.
  5. Маркина С. С., Максимова Н. М., Лазикова Г. Ф. Заболеваемость дифтерией в России в настоящее время // Журн. микробиол. - 2005. - № 1. - С. 31-37.
  6. Ройт А., Бростофф Дж., Мейл Д. Иммунология: Пер. с англ. - М., 2000. - С. 582.
  7. Харченко Г. А., Чанпалова Л. С., Харченко О. Г., Назарочкина О. Б. Дифтерия у привитых детей // VI Российский съезд врачей-инфекционистов. - СПб., 2003. - С. 413-414.
  8. Anttila M., Eskola J., Ahman H., Kayhty H. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjuges and boosted with polysaccharide or conjugate vaccine // J. Infect. Dis. - 1998. - Vol. 177, N 8. - P. 1614-1621.
  9. Bottiger B., Jensen I. P. Maturation of rubella IgG avidity over time after acute rubella infection // Clin. Diagn. Virol. - 1997. - Vol. 8, N 2. - P. 105-111.
  10. Campbell J. D., Lagos R., Levine M. M., Losonsky G. A. Standard alternative regimens of Haemophilus influenzae type B conjugate vaccine (polyribosylribotop phosphate-tetanus toxoides conjugate vaccine) elicit comparable antibody avidities in infants // Pediatr. Infect. Dis. J. - 2002. - Vol. 21, N 9. - P. 822-826.
  11. Eggers M., Bader U., Enders G. Combination of microneutralization and avidity assays: improved diagnosis of recent primary human cytomegalovirus infection in single serum sample of second trimester pregnancy // J. Med. Virol. - 2000. - Vol. 60, N 3. - P. 324-330.
  12. Goldblatt D., Vaz A. R., Miller E. Antibody as a surrogate marker of successful priming by Haemophilus influenzae type B conjugate vaccine fllowing infant immunization // J. Infect. Dis. - 1998. - Vol. 177, N 6. - P. 112-115.
  13. Le Guiloou H., Le Meur A., Bourdon S. et al. Antibody avidity: use for the diagnosis of HIV early infection // Ann. Biol. Clin. - 2001. - Vol. 59, N 1. - P. 41-47.
  14. Longworth E., Borrow R., Goldblatt D. et al. Avidity maturation following vaccination with a meningococcal recombinant hexavalent Por A OMV vaccine in UK infants // Vaccine. - 2002. - Vol. 20, N 19-20. - P. 2592-2596.
  15. Nuorimaa T., Dagan R., Vakevainen M. et al. Avidity and ubclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminium adjuvant // J. Infect. Dis. - 2001. - Vol. 183, N 9. - P. 121-125.
  16. Pullen G. R., Fitzgerald M. G., Hosking C. S. Antibody avidity determination by ELISA using thiocyanate elution // J. Immunol. Meth. - 1986. - Vol. 106, N 1. - P. 119-125.
  17. Shubert J., Zens W., Weissbrich B. Comparative evaluation of the use of immunoblots and of IgG avidity assays as confirmatory test for the diagnosis of acute EBV infections // J. Clin. Virol. - 1998. - Vol. 11, N 3. - P. 161-172.
  18. Suligoy B., Galli C., Massi M. et al. Precision and accuracy of a procedure for detection recent human immunodeficiency virus infections by calculating the antibody avidity index by an automated immunoassay based method // J. Clin. Microbiol. - 2002. - Vol. 40, N 11. - P. 4015-4020.
  19. Tseneva G. Ya., Nikolaeva A. M., Kraeva L. A. Definition high-avidity antibodies and their value in protection against a diphtheria // 9-th International Meeting of the European Laboratory Working Group on Diphtheria, ELGWD and Diphtheria Surveillance Network (DIPNET). - Vouliagmeni, 2006. - P. 56.
  20. Usinger W. R., Lucas A. N. Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides // Infect. and Immun. - 1999. - Vol. 67, N 11. - P. 2366-2370.
  21. Vermont C. L., Van Dijken H. H., Van Limp C. J. et al. Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine // Infect. and Immun. - 2002. - Vol. 70, N 2. - P. 584-590.
  22. Ward K. N., Turner D. J., Couto-Parada X., Thiruchelvam A. D. Use of immunoglobulin G antibody avidity for differentiation of primary human herpesvirus 6 and 7 infections // J. Clin. Microbiol. - 2001. - Vol. 39, N 3. - P. 959-963.
  23. Wuorimaa T., Dagan R., Vakevainen M. et al. Avidity and subclasses of IgG after immunization of infants with an 11. Valent pneumococcal conjugate vaccine with or without aluminium adjuvant // J. Infect. Dis. - 2001. - Vol. 184, N 9. - P. 1211-1215.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Eco-vector, 2011


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: № 014448 от 08.02.1996. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80652 от 15.03.2021 .


##common.cookie##